Skip to content

The Effects of Transcranial Direct Current Stimulation on Executive Function in People With Mild to Moderate Dementia

The Effects of Transcranial Direct Current Stimulation on Executive Function in People With Mild to Moderate Dementia

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03753191
Enrollment
80
Registered
2018-11-26
Start date
2019-06-01
Completion date
2021-10-20
Last updated
2020-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dementia, Executive Function, Transcranial Direct Current Stimulation

Brief summary

To study the effects of transcranial direct current stimulation on executive function in people with mild to moderate dementia

Detailed description

Extensive research had shown executive dysfunction in people with dementia (PWD) is associated with functional abnormalities in prefrontal regions such as the right inferior frontal gyrus (Right IFG) or the left dorsal lateral pre-frontal cortex (Left DLPFC) . Clinical studies suggest that tDCS may be a useful therapeutic tool. Post-tDCS improvements have also been shown in visuo-motor coordination of healthy controls and performance in working memory. The aim of this study is to investigate the effect of tDCS stimulation over left DLPFC or right IFG on attention, inhibition and working memory and their neural correlates in people with dementia (PWD) and healthy controls (HC).This study is planned as a double-blinded, randomized case-control interventional study with a duration of 30 months.

Interventions

DEVICEtranscranial direct current stimulation

Each subject will undergo one tDCS stimulation session lasting for 20 minutes. A constant current of 2 mA will be applied with a linear fade in, fade out of 10 seconds to prevent electrical transients.

Sponsors

The Hong Kong Polytechnic University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

double-blinded, with randomized case-control

Intervention model description

double-blinded, randomized case-control interventional study

Eligibility

Sex/Gender
ALL
Age
65 Years to 90 Years
Healthy volunteers
Yes

Inclusion criteria

* PWD must be aged at least 65 years or above when informed consent is obtained in the presence of his / her first degree relatives. * PWD must meet criteria of DSM-V for dementia as well as for historical diagnosis of dementia. * PWD must have a Chinese MoCA score \> 19 (mild to moderate cognitive deficits) at screening. * Subjects (both PWD and HC) must be physically healthy, and must be able to understand and be willing to sign the informed consent document

Exclusion criteria

* Subject with major neurological illness. * Subject with other diagnosed psychiatric disorders * Subjects reported with history of substance abuse, which including alcohol, drugs or any medication which is indicative of chronic abuse. * Failures to comply with the study protocol or to follow the instructions. * Self-reported with known skin diseases or skin allergy history. * Self-reported with metallic implants, dentures * Self-reported with history of claustrophobia. (This is excluded because subject needs to stay in a quiet room with the head-mounted fNIRS and tDCS, which may elicit their feeling of anxiety)

Design outcomes

Primary

MeasureTime frameDescription
Haemodynamic changesbaseline and 5 minutes after tDCSChange in hemodynamic level in two region of interest of prefrontal cortical regions, that is DLPFC and IFG
Trail Making Testbaseline and 5 minutes after tDCSchange in Trail Making Test
Behavior changebaseline and 5 minutes after tDCSChange in the Chinese Multiple Errands Test
N-back taskbaseline and 5 minutes after tDCSChange in N-back task
Stop-signal taskbaseline and 5 minutes after tDCSChange in Stop-signal task

Countries

Hong Kong

Contacts

Primary ContactFrank LAI, PhD
frank.hy.lai@polyu.edu.hk2766 6749

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026